Neuroleptic malignant syndrome (NMS): challenge with zuclopenthixol and follow-up--a case report.
In view of its receptor-binding profile, zuclopenthixol was used for NMS-challenge in the past 2 years. In 2 patients uneventful challenge took place. One patient showed recurrence of NMS. This occurrence may have been due to challenge shortly after the first episode had abated, and to use of a relatively high dose of zuclopenthixol. Differences in results of challenge showed no relationship with findings on follow-up: the patients who suffered recurrence had an uneventful recovery. One of the others showed a persisting organic amnestic syndrome, lasting now for more than 1.5 year, with EEG disturbances. The last patient rapidly developed tardive dyskinesia, despite the fact that he was treated with neuroleptics for a relatively short time. A hypothesis concerning these effects is presented.
Kemperman
C J
CJ
Department of Psychiatry, State University Hospital, Groningen, The Netherlands.
van den Hoofdakker
R H
RH
D000328:Adult; D003006:Clopenthixol; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D004569:Electroencephalography; D005260:Female; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis*; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D014268:Trifluoperazine / Q000009:adverse effects
D014268:Trifluoperazine; D003006:Clopenthixol; D006220:Haloperidol